NHS Costs

Atorvastatin is the most dispensed drug in England at 65 million items in 2023/24.

Between 2004 and 2018, the NHS spent £6.3 billion on statins in primary care.

Research suggests £2.8 billion, approximately forty percent, could have been saved through optimal prescribing.

For secondary prevention in people with existing heart disease, the benefit is clear: NNT of 15 to 33 to prevent one death over 5 years.

For primary prevention in otherwise healthy people, the Cochrane meta-analysis found an NNT of 138 to prevent one death over 5 years.

For the lowest risk patients now eligible under NICE's 2014 expanded threshold, the NNT rises to 400.

The number needed to harm for new onset diabetes is 99 over 5 years.

For muscle pain, approximately twenty one.

Obesity-attributable NHS costs in England reached £6.5 billion in 2022, with projections suggesting this will rise to £9.7 billion by 2050 if current trends continue.

Obesity is a metabolic consequence of the modern food environment, not a failure of individual willpower. Ultra-processed foods are engineered to override satiety signalling; the NHS pays the medical bill for conditions the food industry is paid to create.

The total societal cost of obesity including lost earnings, benefits and social care is estimated at over £58 billion per year, making it among the most expensive public health crises in British history.

The GP Patient Survey (2024) found that 34.2% of patients described their experience of making a GP appointment as "not good" or "fairly poor." IPSOS polling data and BMA analysis showed that the average wait time for a routine GP appointment in England rose from approximately 1.3 days in 2010 to 13.4 days in 2024. In some regions, the wait exceeds 28 days. Over 6 million patients per month contact their GP practice but fail to get an appointment on first attempt.

This is because the number of fully qualified, full-time equivalent GPs in England fell from 29,364 in September 2015 to 27,200 in September 2023, a loss of over 2,100 GPs despite rising population. GP partnerships are collapsing: the BMA reported that 338 GP practices closed between 2015 and 2023. The average GP patient list grew from 1,573 to 2,293 patients per full-time GP over the same period. Each consultation that does not happen in primary care becomes an A&E attendance or an emergency admission.

The NHS Long Term Workforce Plan (2023) promised 6,000 additional GPs by 2036/37. Previous targets (5,000 additional GPs by 2020, set in 2015) were not met. GP training places have increased, but attrition exceeds recruitment: 39% of GPs plan to leave or reduce hours within 5 years according to the BMA 2023 workforce survey. The GP model, in which a single clinician manages a panel of 2,000+ patients across all conditions, is structurally unsustainable at current staffing.

The Soft Drinks Industry Levy has generated cumulative revenue exceeding £1.2 billion since April 2018.

It drove a 47% reduction in sales-weighted average sugar content of levied drinks between 2015 and 2024.

89% of soft drinks now fall below the 5g per 100ml threshold.

Evidence suggests a 12% relative reduction in hospital dental admissions for children.

The levy prevented up to 5,000 cases of obesity in primary school girls.

Henry Dimbleby's National Food Strategy recommended extending this model to a broader sugar and salt reformulation tax, estimated to raise £3 billion per year.

The government rejected the recommendation. Boris Johnson said the government did not want to start putting new taxes on the food and drink industry.

Pirmohamed et al. (2004) conducted a prospective analysis of 18,820 admissions to two NHS hospitals over six months and found that 6.5 per cent of all admissions were caused by adverse drug reactions (ADRs). The median bed stay for ADR admissions was eight days, compared with six for non-ADR admissions. Extrapolated nationally, ADRs cause an estimated 250,000 hospital admissions per year in England alone, costing the NHS approximately £466 million in direct hospital costs.

This is because polypharmacy multiplies drug-drug interaction risk exponentially. A patient on five medications has a 50 per cent probability of at least one clinically significant drug interaction. At ten medications, that probability exceeds 100 per cent (certainty). The total cost including primary care consultations, ambulance callouts, extended care and follow-up prescriptions to manage ADR symptoms is estimated at £1.1 billion annually (NICE 2015).

The most common ADR-causing drugs are NSAIDs (gastrointestinal bleeding), anticoagulants (haemorrhage), diuretics (electrolyte imbalance) and antidepressants (falls in elderly patients). Each of these is frequently prescribed to manage symptoms of conditions that are themselves caused or exacerbated by nutritional deficiency, chronic inflammation from seed oils, or metabolic dysfunction from processed food consumption.

The NHS spends an estimated £27 to £40 billion every year treating conditions driven primarily by diet.

Type 2 diabetes alone costs £10.7 billion in direct NHS costs, consuming approximately ten percent of the total NHS budget.

£6.2 billion of that goes to treating preventable complications.

Cardiovascular disease adds another £7.4 billion in direct NHS costs, with wider economic losses of £15.8 billion.

Dental caries is the most common reason for hospital admissions in children aged 5 to 9, costing £3.4 billion per year.

Meanwhile the public health prevention grant stands at just £3.6 billion, a ratio of roughly 5 to 1 in favour of drugs over prevention.

That prevention budget has been cut 28% per person in real terms since 2015.

Type 2 diabetes costs the NHS £10.7 billion per year in direct costs.

£6.2 billion of that goes to treating potentially preventable complications.

£4.4 billion covers routine care.

Diabetes consumes approximately ten percent of the total NHS budget.

This figure is projected to reach £16.9 to £18 billion by 2035.

NHS BSA data shows £1.92 billion spent specifically on diabetes medications, with spending having doubled in a decade.

The condition is driven overwhelmingly by diet and lifestyle factors that the NHS does almost nothing to prevent.

NHS England's 2024-25 budget stands at £181.4 billion, representing roughly six per cent of UK GDP and more than double the real-terms spending of 2000.

The overwhelming majority of this expenditure addresses the downstream consequences of preventable chronic disease: cardiovascular conditions, type 2 diabetes, obesity-related illness and mental health disorders that have each risen sharply over the same period.

A system designed around treatment rather than prevention structurally guarantees rising costs as diet and lifestyle deteriorate. The budget reflects not the cost of healthcare but the cost of modern food.

NHS England referral-to-treatment data shows the total waiting list in England reached 7.6 million in January 2024, compared with 2.5 million in 2010 and 4.4 million in March 2020 (pre-pandemic). The 18-week treatment target, a constitutional standard since 2008, was last met in February 2016. In January 2024, 310,000 patients had been waiting over 52 weeks, and 7,800 had been waiting over 65 weeks.

This is because NHS capacity has not expanded in proportion to demand. England has 2.4 acute beds per 1,000 population, compared with the OECD average of 4.3. The GP workforce grew by 2.1% between 2015 and 2023, while the registered patient list grew by 7.5%. Hospital consultant posts have a 6.5% vacancy rate nationally. Demand is driven by an ageing population and rising chronic disease prevalence, much of it diet-related: type 2 diabetes, cardiovascular disease, obesity-related conditions.

The waiting list is not simply a post-pandemic backlog. It has been structurally growing since 2012. The NHS was designed in 1948 to treat acute illness in a population with a life expectancy of 66 years. It now manages chronic disease in a population with a life expectancy of 81 years, on a budget that has averaged 1.4% real-terms annual growth since 2010, compared with the 3.7% long-term average required to maintain service levels (IFS 2023).

Diabetes UK (2024) reports that the NHS spends approximately £10 billion per year on diabetes, representing nearly 10% of the total NHS budget. Of this, approximately 80% is spent on managing complications (amputations, blindness, kidney dialysis, cardiovascular events) rather than addressing the underlying metabolic dysfunction. The UK has 4.3 million people diagnosed with diabetes and an estimated 850,000 undiagnosed, with projections reaching 5.5 million by 2030.

This is because type 2 diabetes (90% of cases) is driven primarily by diet and lifestyle, yet the standard NHS treatment pathway focuses on pharmaceutical management. Metformin, sulphonylureas, DPP-4 inhibitors, GLP-1 agonists and eventually insulin are prescribed in sequence, each adding cost without resolving the underlying insulin resistance. Lean et al. (2018, Lancet) demonstrated that a structured dietary intervention achieved 46% remission of type 2 diabetes at 12 months.

The NHS Long Term Plan (2019) committed to doubling the NHS Diabetes Prevention Programme, yet diabetes diagnosis rates have continued to accelerate. Each new diagnosis represents approximately £9,000 per year in direct healthcare costs. A disease that is demonstrably reversible through dietary intervention continues to be managed as a chronic pharmaceutical condition because the economic incentives favour treatment over cure.

NHS England Referral to Treatment data for January 2024 showed 7.61 million patient pathways waiting to start consultant-led treatment, approximately one in eight of the population. The list stood at 4.43 million pre-pandemic, meaning it grew 72% in four years. Over 300,000 had waited longer than one year.

This is because NHS capacity has not kept pace. The UK has 2.4 hospital beds per 1,000 population versus the OECD average of 4.3 and Germany at 7.8. General and acute beds fell from 170,000 in 1987 to 101,000 in 2023 while the over-65 population grew from 8.7 to 11.5 million.

The NHS increasingly functions as an emergency service. A 12-month wait for a hip replacement means 12 months of reduced mobility, muscle atrophy and secondary depression. The waiting list is not an administrative backlog but a systematic degradation of health outcomes through delay, disproportionately affecting those who cannot afford private alternatives.

Total NHS medicines spending reached £19.9 billion in 2023/24.

The public health grant to local authorities stood at just £3.6 billion.

That is a ratio of roughly 5 to 1 in favour of drugs over prevention.

The public health grant has been cut 28% per person in real terms since 2015/16.

The proportion of health spending on prevention fell from just over 5% to 4.5% between 2014 and 2019.

The total DHSC budget for 2024/25 is £204.7 billion.

With approximately thirty eight million UK income taxpayers, that equates to roughly £5,387 per taxpayer per year for NHS England alone.

Diet-related diseases cost an estimated £27 to £40 billion of that annually. Your taxes treat the symptoms. Almost nothing prevents the causes.